The Latest Cardiac and Vascular News
MARLBOROUGH, Mass., Oct. 23, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the District Court of Dusseldorf, Germany has determined that Edwards Lifesciences Corporation’s Sapien 3 Ultra™ device infringed a patent – established by Symetis SA, a subsidiary of Boston Scientific – specific to the fabric used on the […]
MARLBOROUGH, Mass., Sept. 24, 2018 /PRNewswire/ — Today, Boston Scientific (NYSE :BSX ) announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA) application to market the Eluvia™Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease (PAD). The Eluvia stent utilizes a drug-polymer combination to offer […]
MARLBOROUGH, Mass., Sept. 17, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE :BSX ) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego, on September 21 – September 25. Data from the head-to-head IMPERIAL trial evaluating the ELUVIA™ […]
MARLBOROUGH, Mass., Aug. 8, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized the VICI VENOUS STENT® System for treating venous obstructive disease. Boston Scientific has been an investor in VENITI since 2016 and currently […]
MARLBOROUGH, Mass., July 25, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.490 billion during the second quarter ended June 30, 2018. This represents growth of 10.3 percent on a reported basis, 8.6 percent on an operational1 basis and 7.9 percent on an organic2 basis, all compared to the prior year period. The company reported […]
MARLBOROUGH, Mass., July 20, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel® Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter […]
MARLBOROUGH, Mass., July 5, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Cryterion Medical, Inc., a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation (AF). The addition of this cryoballoon platform positions the company as the first to have both cryothermal […]
Report: Stryker puts in takeover bid for Boston Scientific JUNE 11, 2018 BY FINK DENSFORD Stryker (NYSE:SYK) has put in a bid as it looks to acquire rival Boston Scientific (NYSE:BSX), according to a new report from the Wall Street Journal. Boston Scientific has not actively responded to the approach, according to the report, which came […]
MARLBOROUGH, Mass., May 16, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 22-25. During the late-breaking sessions on Wednesday, May 23, data from the RESPOND trial will provide two-year, ‘real world’ […]
MARLBOROUGH, Mass., May 14, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34th Annual Strategic Decisions Conference on May 31, 2018 in New York. Mike Mahoney, chairman and chief executive officer, will participate in a 50-minute presentation and question-and-answer session with the host analyst beginning at approximately 8:00 a.m. EDT. A live […]
